SavedAdd your journal

Journals / Annals of Medical Research / 2021 / Cilt: 28 - Sayı: 1

The effectiveness of olmesartan on inflammation at cardiopulmonary bypass

İbrahim Murat ÖZGÜLER
Latif ÜSTÜNEL
Pages
31–36
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Samples were taken before the induction of anesthesia (T1), 5 minutes before cross clamping (T2), 5 minutes after cross clamping (T3), after protamine infusion (T4), postoperative day 3 (T5) and postoperative day 35 (T6) for total serum levels of IL-6, IL-10 and IL-18; for h-CRP levels preoperative (T1) and postoperative day 35 (T2).Results: Statistically significant decrease of CRP levels were observed on the postoperative 35th day in Group O (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Systemic inflammatory response syndrome may develop after coronary artery bypass graft surgery that performed by cardiopulmonary bypass technique.
📊
Key Findings & Data:The antiinflammatory efficacy of olmesartan treatment was investigated in patients undergoing cardiopulmonary bypass.Materials and Methods: The study included 50 patients (14 female, 36 male) between 30-80 years of age were underwent CABG surgery.
💡
Conclusion & Impact:Samples were taken before the induction of anesthesia (T1), 5 minutes before cross clamping (T2), 5 minutes after cross clamping (T3), after protamine infusion (T4), postoperative day 3 (T5) and postoperative day 35 (T6) for total serum levels of IL-6, IL-10 and IL-18; for h-CRP levels preoperative (T1) and postoperative day 35 (T2).Results: Statistically significant decrease of CRP levels were observed on the postoperative 35th day in Group O (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Systemic inflammatory response syndrome may develop after coronary artery bypass graft surgery that performed by cardiopulmonary bypass technique. It is known that olmesartan, an angiotensin II receptor blocker, has anti-inflammatory effects. The antiinflammatory efficacy of olmesartan treatment was investigated in patients undergoing cardiopulmonary bypass.Materials and Methods: The study included 50 patients (14 female, 36 male) between 30-80 years of age were underwent CABG surgery. Patients were randomly assigned to control (Group C) and olmesartan (Group O) gruoups. Group O were treated with a single dose of 10 mg per day; 5 days preoperatively and 35 days postoperatively, 30 mg at the operation day. Samples were taken before the induction of anesthesia (T1), 5 minutes before cross clamping (T2), 5 minutes after cross clamping (T3), after protamine infusion (T4), postoperative day 3 (T5) and postoperative day 35 (T6) for total serum levels of IL-6, IL-10 and IL-18; for h-CRP levels preoperative (T1) and postoperative day 35 (T2).Results: Statistically significant decrease of CRP levels were observed on the postoperative 35th day in Group O (p

🔖

Cite This Article

ÖZGÜLER, İ. M., ÜSTÜNEL, L. (2022). The effectiveness of olmesartan on inflammation at cardiopulmonary bypass. Annals of Medical Research, Cilt: 28 - Sayı: 1, 31–36. https://ajindex.com/articles/445862

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Schwartz D, Taberdel Y, Presier JC, et al. Does aprotinin influence the inflammatory response to cardiopulmaonary bypass in patients? J Thorac Cardiovasc Surg 2003;125:184-90
  2. Laffey JG, Boylan JF, Cheng DHC. The systemic inflammatory response to cardiac surgery. Anesthesiology 2002;199:215-52
  3. Paperalla D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiolgy and treatment. An update. Eur J Cardiothorac Surg 2002;21:232-44
  4. Hornick P, Taylor KM. Immune and inflammatory responses after cardiopulmonary bypass. In: Gravlee GP, Davis RF, Kurusz M, et al. Eds. Cardiopulmonary bypss: practice and principles, 2nd ed. Philadelphia: Lippincott Williams & Wilkins 2000:303-10
  5. Brix-Christensen V. The systemic Inflammatory response after cardiac surgery with cardiopulmonary bypass in children. Acta Anaesthesiol Scand 2001;45:671-9
  6. El Azab SR, Roseel PM, de Lange JJ, et al. Dexamethasone decreases the pro-to antiinflammatory cytokine ratio during cardiac surgery. Br J Anaesth 2002;88:496-501
  7. Giomarelli P, Scolletta S, Borelli E, et al. Myocardial and lung injury after cardiopulmonary bypass: role of interleukin (IL)-10. Ann Thorac Surg 2003;76:117-23
  8. Proudfoot JM, Croft KD, Puddey IB, et al. Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1. J Pharmacol Exp Ther 2003;305:846-53
  9. Sherwood ER, Toliver-Kinsky T. Mechenisms of inflammatory response. Best Practice Research Clinical Anesthesiolgy 2004;18:385-405
  10. Kirshfink M. Controlling the complement system in inflammation. Immunopharmacology 1997;38:51-62
  11. Wan S, Yim AP. Cytokines in myocardial injury: impact on cardiac surgical approach. Eur J Cardiothorac Surg 1999;16:107-11
  12. Oppenheim JJ and Saklatvala J. Clinical Applications of Cytokines. (ed J.J. Oppenheim J, Rossio L and Geraing J.H.) Oxford UniversityPres, Newyork 1993: 3-15
  13. Teranishi T, Hirano T, Arima N, et al. Human helper T cell factor(s) (ThF), II: induction of IgG production in B lymphoblastoid cell lines and identification of T cell-replacing factor- (TRF) like factor(s). J Immunol 1982;128:1903-8
  14. Xing Z, Gauldie J, Cox G, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998;101:311-20
  15. Fickenser H, Hor S, Kupers H, et al. The IL-10 family of cytokines. Trends Immunol 2002;2